Date: 2016-05-25
Type of information: Nomination
Compound:
Company: Alder Biopharmaceuticals (USA - WA)
Therapeutic area: Inflammatory diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: • On May 25, 2016, Alder BioPharmaceuticals announced the expansion of its leadership team to support the advancement of ALD403 for migraine prevention. Iqbal Husain, Ph.D., was appointed vice president of program and portfolio management, Dauphine Barone was promoted to vice president of manufacturing logistics, and Barbara Schaeffler, MBA, was promoted to vice president of clinical operations. Dr. Husain brings over 20 years of experience in global biopharmaceutical product development and program management and is responsible for aligning and integrating cross functional activities to better ensure the success of Alder's product candidates. Prior to joining Alder, he served as vice president of project management of CTI BioPharma, where he led program management of all oncology development and commercial programs. From 1995 to 2013, he served in various leadership positions at Amgen including executive director of program management and strategic operations, associate director of Japan Representative Office, and international product development manager, Asia Pacific Latin America. Prior to that, Dr. Husain was the director of research and development at Lectin Biopharma and a development manager at PDx Technologies. He received his Ph.D. in biochemistry and B.Sc. in physiology and biochemistry from the University of Leeds, U.K. Ms. Barone has more than 30 years of life sciences research and development experience and is responsible for leading manufacturing supply and logistics for Alder products, including planning and supervision of contract manufacturing. She joined Alder in 2007 as director, program management, and was promoted to senior director, manufacturing logistics, in 2013 with responsibility for contract manufacturing organization (CMO) business relationship management for the entire Alder portfolio of product candidates. From 2003 to 2007, Ms. Barone served first as staff scientist and then as project manager at Trubion Pharmaceuticals leading cross-functional teams tasked with developing drug candidates. From 1989 to 2003, she served as a research scientist, holding positions of increasing responsibility at Amgen/Immunex. Ms. Barone holds a B.S. in biology from the University of California, Riverside. Ms. Schaeffler has more than 20 years of experience in clinical development and operations and is responsible for clinical operations in the development of ALD403. She joined Alder in 2012 as senior director, clinical operations, and has been responsible for all the operational aspects of clinical trials conducted by the company. Prior to Alder, she served as a senior clinical consultant for Phase 2 and 3 clinical trials in oncology. From 2004 to 2010, Ms. Schaeffler held positions of increasing responsibility for clinical operations at Poniard Pharmaceutical, and from 1996-2004 held positions of increasing responsibility in clinical development at Chiron Corporation (formerly PathoGenesis). Ms. Schaeffler holds an MBA from City University of Seattle and a B.A. in bacteriology from the University of California, Davis.
Financial terms:
Latest news:
